Use WebMD’s Pill Identifier to find and identify any over-the-counter or prescription drug, pill, or medication by color, shape, or imprint and easily compare pictures of multiple drugs.

Use our Pill Identifier tool to instantly match by imprint, shape, color, drug name, or NDC code. Access over 11,500 drug images, updated daily.

很喜歡「階梯閱讀空間」讓我自選喜愛的文章!我能補做練習，又可針對錯誤即時看答案，幫助我增加對詞彙的認識。 學生、家長齊讚好. 「階梯閱讀空間」很優質，比坊間的中文網站更優勝!

2016年7月1日 · Crenezumab is a humanized anti-amyloid-beta (Aβ) monoclonal IgG4 antibody in development for the treatment of Alzheimer’s disease (AD). Crenezumab binds monomeric and aggregated Aβ species and may reduce their neurotoxicity and accumulation.

Our pill identifier tool allows you to ID prescription drugs, over the counter (OTC) medications, and generic or brand name pills and capsules using a variety of methods. You can search using the imprint, size, name/ingredients, national drug code (labeler or product code), color, or shape.

2019年4月9日 · Two global, randomized, double-blind, placebo-controlled, Phase III studies (CREAD; CREAD2, NCT03114657]) are testing the efficacy and safety of crenezumab (60 mg/kg) in prodromal-to-mild AD.

2022年11月1日 · Interventions: Participants received placebo or 60 mg/kg crenezumab intravenously every 4 weeks for up to 100 weeks. Main outcomes and measures: The primary outcome was change from baseline to week 105 in Clinical Dementia Rating …

【新闻事件】：今天罗氏旗下基因泰克与合作者AC Immune宣布将终止粉状蛋白抗体crenezumab的两个三期临床CREAD 1、CREAD 2，因为独立监察委员会对这个针对早期AD人群试验的中期分析显示该试验成功可能性很小。 但这个药物在哥伦比亚高危人群进行的一个AD预防试验还会继续，另一个针对可溶性粉状蛋白的抗体gantenerumab的两个三期临床（GRADUATE1、GRADUATE2）也还会继续。 受此消息影响，不仅AC Immune股票下 …

We, at Truemeds make a diligent attempt to deliver accurate, expert- drafted and thoroughly reviewed medicine related information to our consumers. However, it should, by no means, be considered a substitute for prescription from a certified doctor or a …

2019年2月1日 · 1月30日，罗氏宣布终止crenezumab 治疗早期阿尔茨海默病患者(前驱或轻度AD患者)的两项III期CREAD I和CREAD 2临床研究。罗氏做此决定主要是独立数据监测委员会的期中分析一线结果显示crenezumab 可能无法到达改善患者的临床痴呆综合汇总评定量表评分(CDR-SB评 …